Managed Care Review Board™ Presents - Managed Care Strategies to Optimize Overall Outcomes in Multiple Myeloma

Learn About:

• Current evidence-based recommendations for the assessment and treatment of multiple myeloma (MM)
• Current and emerging agents for the treatment of MM
• Sequencing options for MM treatments
• Key components of assessing the total cost of care for various treatment options in MM

Expert Faculty Presenters

Ryan Haumschild, PharmD, MS, MBA, CPEL Vice President of Ambulatory Pharmacy Emory Healthcare and Winship Cancer Institute Click here for biography Michael Kobernick, MD, MS, MS-PopH, CPE Senior Medical Director – Health Plan Business Blue Cross Blue Shield of Michigan Lecturer Jefferson College of Population Health Click here for biography Hans Lee, MD Associate Professor Director, Multiple Myeloma Clinical Research Division of Cancer Medicine M. D. Anderson Cancer Center Click here for biography Sita Bhatt, PharmD, BCOP Clinical Pharmacy Specialist Boston Medical Center Click here for biography Yvette D. Patient Advocate

Target Audience
This activity is designed to meet the educational needs of managed care pharmacy directors, registered nurses, clinical pharmacists, quality directors and medical directors.

Statement of Need/Program Overview
Attendees will receive enhanced knowledge and skills regarding evidence-based coverage and reimbursement policies that are based on current clinical practice guidelines for relapsed/refractory multiple myeloma, the evidence for the use of novel agents, and the factors that must be weighed in treatment selection. Additional focus will be on how plans can benefit by leveraging the full potential of multidisciplinary care in the optimal management of relapsed/refractory multiple myeloma.

Educational Objectives
After completing this activity, the participant should be better able to:

• Describe current evidence-based recommendations for the assessment and treatment of MM
• Assess current and emerging agents for the treatment of MM based on efficacy, safety, and prior lines of therapy
• Outline the sequencing options for MM treatments to support the development of drug formularies and treatment algorithms
• Discuss the key components of assessing the total cost of care for various treatment options in MM

Accreditation Information

Joint Accreditation Statement In support of improving patient care, this activity has been planned and implemented by Medical Education Resources (MER) and Impact Education, LLC. MER is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team

Physician Continuing Medical Education
Medical Education Resources designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
Medical Education Resources designates this live activity for a maximum of 1.5 ANCC nursing contact hours. Nurses will be awarded contact hours upon successful completion of the activity.

Medical Education Resources is a provider of continuing nursing education by the California Board of Registered Nursing, Provider #CEP 12299, for 1.5 contact hours.

Continuing Pharmacy Education
Medical Education Resources designates this continuing education activity for 1.5 contact hour(s) (0.15 CEUs) of the Accreditation Council for Pharmacy Education.

UAN:JA0003680-9999-24-174-L01-P
Activity Type: Knowledge-based

Disclosure of Conflicts of Interest
Medical Education Resources ensures balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, MER identifies all financial relationships with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Reported financial relationships are mitigated by MER to ensure that all scientific research referred to, reported, or used in a CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing learners with high-quality CE activities that promote improvements or quality in health care and not the business interest of an ineligible company.

The authors reported the following financial relationships with ineligible companies whose products or services may be mentioned in this activity:

The content managers reported the following financial relationships with ineligible companies whose products or services may be mentioned in this activity:

DISCLAIMER
The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Medical Education Resources, Impact Education, LLC, and/or Regeneron Pharmaceuticals, Inc. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.

FEE INFORMATION
There is no fee for this educational activity.

Please note: Registration for AMCP Nexus 2024 is NOT required to attend this symposium.